Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing Guggenhime surrendered shares to cover tax withholding on vesting RSUs, retaining about 164,000 shares valued at $10.12 million.
A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should Know Wassil exercised options at a steep discount and surrendered shares for tax withholding, maintaining a 0.1% ownership stake following the transactions.
Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm The stock has surged 95% over the past year, and the CEO retains about 447,000 direct shares plus indirect holdings.
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases.
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on metabolic and pulmonary conditions.
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors.
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares This clinical-stage biotech develops therapies for rare muscle diseases, leveraging its FORCE platform to target significant unmet needs.
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting retinal and glaucoma conditions.
Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway cancers, advancing a pipeline of novel oncology candidates.
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding This biotechnology firm develops precision therapies for rare, genetically defined diseases, with a focus on targeted cancer treatments.
This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know This clinical-stage biotech develops antibody therapies for thyroid eye disease, advancing multiple candidates through its R&D pipeline.
This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in oncology treatment.
Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish This clinical-stage biotech focuses on targeted cancer therapies and strategic partnerships in oncology and rare disease treatment.
The Small-Cap Renaissance: Why the Russell 2000 is Leading the Charge in 2026 As of March 9, 2026, a dramatic regime shift is unfolding on Wall Street. After years of playing second fiddle to the "Magnificent Seven" and AI-driven mega-caps, small-cap stocks have emerged as the surprise leaders of the 2026 market. The Russell 2000 Index (NYSEArca: IWM) has surged over 6% year-to-date,
Vaxcyte's Chief Technical Ops Officer Sells Shares Focused on next-generation vaccines for bacterial diseases, this biotech just reported a notable insider sale amid a challenging year.
Thermo Fisher Launches Four-Part Bond Offering Ahead Of Possible Government Shutdown Thermo Fisher sells four-part dollar bonds as U.S. investment-grade issuance tops $200 billion, with yields near historic lows and spreads tight.
Merck Advances Childhood Pneumococcal Care With Promising Vaccine Data Merck's Capvaxive vaccine showed strong immune responses and a comparable safety profile to PPSV23 in high-risk children during the Phase 3 STRIDE-13 trial.
